


**Remarks**

Claims 10-15 might be considered duplicates of each other. To avoid this, new claim 16, directed to a composition comprising a compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable adjuvant, has been added to the application; and claims 10-15 have been converted to method of use claims.

Respectfully submitted,

Shigeki SETO et al.

By:   
Michael R. Davis  
Registration No. 25,134  
Attorney for Applicants

MRD/pth  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
December 22, 2004